					·.		Page 1 of 1	
Form P	TO-1449	(modified)		Atty. Docket No.: Serial No.: UVMO:023US 10/520,408				
List of Patents and Publications for Applicant's				Applicant:				
				Thomas P. Quinn Natalia G. Karasseva				
Info	ORMATION	DISCLOSURE STA	TEMENT					
	(Use sev	eral sheets if necessary)		Filing Date:	i i	Group:		
T1	· · · · · · · · · · · · · · · · · · ·	•		May 17, 2005	Other Art			
				te Page 1 See Page I				
	,	J						
		Ţ	J.S. Pate	nt Documents				
Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.	
/ALH/	A1	5,578,482	11/26/96	Lippman et al.	435	384	07/26/93	
	A2	5,874,528	02/23/99	Lupu et al.	530	317	10/27/94	
	A3	5,985,553	11/16/99	King et al.	435	6	06/07/95	
	A4	6,414,130	07/02/02	Doherty et al.	536	23.5	07/31/00	
	A5	6,417,168	07/09/02	Greene et al.	514	44	07/08/98	
	A6	6,426,400	07/30/02	Zalutsky	530	330	04/26/00	
∇	A7	6,884,418	04/26/05	Shawver et al.	424	155.1	01/18/91	
		Fo	reign Pa	tent Document	S			
		Document Number	Date	Country	Language			
(Other A	rt (Including	Author,	Title, Date Per	tinent P	ages,	Etc.)	
Exam. Init.	Ref. Des.	Citation						
					· · · · · · · · · · · · · · · · · · ·			

25741146.1

EXAMINER: /Anne Holleran/ (06/23/2007) | **DATE CONSIDERED:**

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. Serial No.			
		UVMO:023US	10/520,408		
List of Patents and Publications for	Applicant's	Applicant			
	•	Thomas P. Quinn			
Information Disclosure S	TATEMENT	Natalia G. Karasseva			
(Use several sheets if necessa	ary)	Filing Date: January 3, 2005	Group: Unknown 1643		
		Patent Documents	Other Art		
		See Page 1	See Page 1		

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

_	xam. Init.	Ref. Des.	Citation McInnes and Sykes, "Growth Factor Receptors: Structure, Mechanism, and Drug Discovery", Biopolymers, 43(5):339-366, 1997.					
-/	ALH/	C11						
		C12	Oldenburg et al., "Peptide ligands for a sugar-binding protein isolated from a random peptide library", Proc. Natl. Acad. Sci., USA, 89:5393-5397, 1992.					
		C13	Piccart, Perry (Ed.), American Soc. Clinical Oncology, Alexandria, VA, Integration of New Therapies Into Management of Metastatic Breast Cancer: A Focus on Chemotherapy, Treatment Selection Through Use of Molecular Markers, and Newly Developed Biologic Therapies in Late Clinical Development. "In: American Society of Clinical Oncology Educational Book", 1999.					
		C14	Weiner et al., "Phase I Trial of 2B1, a Bispecific Monoclonal Antibody Targeting c-erbB-2 and FeγRIII" Cancer Res., 55(20):4586-4593, 1995.					
		C15	Wiechen et al., "C-erbB-2 anti-sense phosphorothioate oligodeoxynucleotides inhibit growth and serum-induced cell spreading of p185 ^{c-erbb-2} overexpressing ovarian carcinoma cells" Int. J. Cancer 63(4):604-608, 1995.					
`	\bigvee	C16	Wrighton et al., "Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin" Science 273, 458-463, 1996.					

25514576.1

EXAMINER: /Anne Holleran/ (06/23/2007) DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

			10176	8				Page 1 of		
Form P	ΓΟ-1449	(modified)	AUG 2 9 2000	Atty. Docket N			Serial No. 10/520,408			
List of Pa	atents an	d Publications fo	Applicant's		947					
			Applicant's 740EMAN STATEMENT	Thomas P. Qui	inn					
INFO	ORMATIO	N DISCLOSURE	STATEMENT	Natalia G. Kar	Natalia G. Karasseva					
				Filing Date:						
	(Use so	everal sheets if necess	ary)	January 3, 200	January 3, 2005 Unknown			643		
U.S	S. Patent	Documents	Foreig	n Patent Document	i i					
	See P	age 1		See Page 1	ee Page 1 See Page 1					
- -			U.S. Pa	tent Docume	ents					
Exam. Init.	Ref. Des.	Document Number			Class	Sub Class	Filing Date of App.			
			•							
			Foreign F	Patent Docum	nents	.				
Exam. Init.	Ref. Des.	Document Number	Date	Country	Clas	s Sul Clas	1	Translation Yes/No		
					÷					
C	Other A	Art (includi	ng Autho	or, Title, Date	Pert	inent F	Pages,	Etc.)		
Exam. Ref. Citation Init. Des.										
/ALH/		Alimandi et al. "Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors", EMBO J, 16(18):5608-5617, 1997.								
	C2	Ballinger et al., "Selection of Heregulin Variants Having Higher Affinity for the ErbB3 Receptor by Monovalent Phage Display", J Biol. Chem., 273(19): 11675-11684, 1998.								
		Receptor by Me	movaient i nag	e Display", J Biol. C	nem., 2	73(19): 11	073-11004,	1998.		
	C3	Baselga et al., " Antitumor Activ	Recombinant I	e Display", J Biol. C Humanized Anti-HEI el and Doxorubicin a ancer Res.,58:2825-2	R2 Antil	oody (Herc	eptin TM) E	nhances the		
	C3	Baselga et al., " Antitumor Activ Breast Cancer >	Recombinant I vity of Paclitax Kenografts", Ca Random Peptio	lumanized Anti-HEI el and Doxorubicin a	R2 Antil gainst F 831, 19	oody (Hero IER2/neu (98.	eptin TM) E Overexpres	nhances the sing Human		
		Baselga et al., "Antitumor Active Breast Cancer > Devlin et al., "Science, 249:40 Disis et al., "Ge	Recombinant Ivity of Paclitax Kenografts", Carandom Peptid 4-406, 1990.	Humanized Anti-HEI el and Doxorubicin a ancer Res.,58:2825-2	R2 Antib against F 831, 199 e of Spe	pody (Herc HER2/neu (98. ecific Prote	eptin TM) E Overexpres in Binding otein in Pat	nhances the sing Human Molecules",		
	C4	Baselga et al., "Antitumor Active Breast Cancer?" Devlin et al., "Science, 249:40 Disis et al., "Ge Breast and Ovan 1297, 1999. Giebel et al., "S	Recombinant Is vity of Paclitax Kenografts", Carandom Peptid 4-406, 1990. Internation of Imprian Cancer Us	Humanized Anti-HEI el and Doxorubicin a ancer Res.,58:2825-2 de Libraries: A Source munity to the HER-2	R2 Antilingainst I 831, 199 e of Sperimen On Vaccine	pody (Herch HER2/neu (1988). ecific Protection Protecti	eptin TM) E Overexpres in Binding otein in Pai ncer Res., 5	mhances the sing Human Molecules", tients with 5(6):1289-		
	C4	Baselga et al., "Antitumor Active Breast Cancer?" Devlin et al., "Science, 249:40 Disis et al., "Ge Breast and Ovar 1297, 1999. Giebel et al., "Streptavidin wird Jones et al., "Bi	Recombinant Invity of Paclitax Kenografts", Carandom Peptid 4-406, 1990. Internation of Imprian Cancer Use Coreening of Cyth High Affinit Inding Interaction	Humanized Anti-HEI el and Doxorubicin a ancer Res.,58:2825-2 de Libraries: A Source munity to the HER-2 ing a Peptide-based vectic Peptide Phage L	R2 Antilingainst F 831, 199 te of Spo /neu On Vaccine ibraries 4:15430	cogenic Protection Called Title	eptin TM) E Overexpres in Binding otein in Pat ncer Res., 5 Ligands Th 95.	mhances the sing Human Molecules", tients with (6):1289- at Bind ErbB4		
	C4 C5	Baselga et al., "Antitumor Active Breast Cancer? Devlin et al., "Science, 249:40 Disis et al., "Ge Breast and Ovar 1297, 1999. Giebel et al., "Streptavidin with Jones et al., "Bi Receptors Asser 1998. Kay et al., "An	Recombinant Ivity of Paclitax Kenografts", Carandom Peptid 4-406, 1990. Interaction of Imprian Cancer Using Creening of Cycle High Affinit Inding Interactions and January M13 phage lib	Humanized Anti-HEI el and Doxorubicin a ancer Res.,58:2825-2 de Libraries: A Source munity to the HER-2 ing a Peptide-based vectic Peptide Phage Lies" Biochemistry, 34 on of the Heregulinß	R2 Antilingainst F 831, 199 te of Spo /neu On Vaccine ibraries 4:15430 egf Doi esis", J.	cody (Herce 1ER2/neu 198.) ccific Protection	eptin TM) E Overexpres in Binding otein in Par ncer Res., 5 Ligands Th 95. ErbB3 and n., 273(9):1	Molecules", tients with 6(6):1289- at Bind ErbB4 1667-11674,		
25514576.1	C4 C5 C6 C9	Baselga et al., "Antitumor Active Breast Cancer? Devlin et al., "Science, 249:40 Disis et al., "Ge Breast and Ovar 1297, 1999. Giebel et al., "Streptavidin with Jones et al., "Bi Receptors Asser 1998. Kay et al., "An	Recombinant Ivity of Paclitax Kenografts", Carandom Peptid 4-406, 1990. Interaction of Imprian Cancer Using Creening of Cycle High Affinit Inding Interactions and January M13 phage lib	Humanized Anti-HEI el and Doxorubicin a sincer Res., 58:2825-2 de Libraries: A Source munity to the HER-2 ing a Peptide-based verice Peptide Phage Lies" Biochemistry, 34 on of the Heregulinß e Scanning Mutagent rary displaying randomary dis	R2 Antilingainst F 831, 199 te of Spo /neu On Vaccine ibraries 4:15430 egf Doi esis", J.	cody (Herce 1ER2/neu 198.) ccific Protection	eptin TM) E Overexpres in Binding otein in Par ncer Res., 5 Ligands Th 95. ErbB3 and n., 273(9):1	Molecules", tients with 6(6):1289- at Bind ErbB4 1667-11674,		

								Page 1 of 2			
Form F	PTO-144	9 (modified)		Atty. Docket N UVMO:023US	Serial No. 10/520,408						
		d Publications for ON DISCLOSURE S		Applicant Thomas P. Quinn							
2005	(Use s	everal sheets if necessa	ry)	Filing Date: January 3, 200	Filing Date: January 3, 2005		Group: Upknown 1643				
MARK OFFICE U	U.S. Patent Documents See Page 1			Foreign Patent Documents See Page 1			Other Art See Page 1				
	<u> </u>		U.S. Pat	tent Docume	nts	-					
Exam. Init.	Ref. Des.	Document Number	Date	Name		Class	Sub Class	Filing Date of App.			
		F	oreign P	atent Docun	nents						
Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Clas	1	anslation Yes/No			
	Other Art (Including Author, Title, Date Pertinent Pages, Etc.)										
Exam. Init.	Ref. Des.	Citation									
/ALH/	C7	Harris et al., "Gene therapy for cancer using tumour-specific prod", Gene Therapy, 1:170-5, (1994).									
/ALH/	C8	Jinno et al., "Effectiveness of an Adriamycin Immunoconjugate that Recognizes the C-erb B-2 Product on Breast Cancer Cell Lines", Surgery today, 26:501-7, (1996).									

25514576.1

/Anne Holleran/ (06/23/2007) **EXAMINER:**

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.